Will Kesimpta (ofatumumab) insurance coverage still be available in 2026?
Whether Kesimpta is covered in 2026 depends mostly on your specific insurer’s formulary (which drugs are covered), benefit design (copay/coinsurance rules), and prior authorization/step-therapy requirements—not on a single universal “coverage year” rule. Insurers can add, restrict, or remove drugs over time as contracts are renegotiated and as utilization and cost-effectiveness change.
In practice, many patients find that coverage in a later year like 2026 depends on whether Kesimpta remains on the insurer’s preferred biologic list (if the plan covers one) and whether the plan tightens prior authorization criteria.
What usually decides your Kesimpta coverage in 2026?
Most coverage decisions for Kesimpta typically turn on:
- Medical necessity criteria (for example, the diagnosis and disease activity status your clinician documents)
- Whether the plan requires prior authorization
- Whether the plan uses step therapy (trying an alternative first), especially for biologics and MS therapies
- Where you receive care (specialty pharmacy vs. clinic-administered pharmacy processes)
- Your plan’s pharmacy benefit vs. medical benefit handling
If your plan already covers Kesimpta in 2025, it is often more likely to continue in 2026—but not guaranteed.
How to check your plan’s Kesimpta status for 2026
To get the most reliable answer for 2026, use one of these approaches with your insurer or pharmacy benefit manager:
- Look up “Kesimpta (ofatumumab)” in your plan’s online formulary and check the “effective dates” or most recent update date.
- Ask your insurer or specialty pharmacy to confirm:
1) Whether it is covered under the pharmacy benefit in 2026
2) Whether prior authorization will be required in 2026
3) Your expected cost share (copay/coinsurance) and deductible impact
- Have your prescriber’s office request prior authorization using the insurer’s current criteria (approval documents often reference the plan year).
What if Kesimpta coverage is restricted, denied, or removed for 2026?
If your insurer denies coverage in 2026, typical next steps include:
- Resubmitting with the documentation your insurer requires for prior authorization
- Requesting an exception/appeal if criteria are not met on paper but your clinician believes it is medically necessary
- Switching to a therapeutically similar MS therapy if your plan changes formulary preferences (your neurologist can advise what options still fit your diagnosis history)
The exact process and forms depend on your plan and state insurance rules.
How do patents and exclusivity affect insurance access in 2026?
Patent and exclusivity status can influence pricing and competition, which can affect coverage decisions over time. To check the most current patent/exclusivity landscape for ofatumumab products and how that might affect market alternatives, DrugPatentWatch.com tracks patent information and can be a helpful starting point for understanding potential future competition effects. [1]
DrugPatentWatch.com does not tell you your individual insurer’s formulary status for 2026, but it can help contextualize why insurers may change preferred options.
Key alternatives if Kesimpta becomes harder to cover in 2026
If coverage becomes more difficult (higher cost share, narrower criteria, or step therapy), the options your insurer may push toward typically include other MS disease-modifying therapies available on that plan. Your neurologist can match the alternatives to your prior treatment history and risk profile. Your plan’s formulary will determine which substitutes are actually covered.
Source to check for future competition signals
- DrugPatentWatch.com (ofatumumab/potential competition context): [1]
If you tell me your insurer name (and whether it’s commercial, Medicare Advantage, or Medicaid) and your state, I can help you narrow down what to ask for in your plan formulary review for 2026 and what denials/appeals language is usually most relevant.
Sources
[1] https://www.drugpatentwatch.com/